Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC)

被引：0
作者：
Gregorc, V.
Novello, S.
Santoro, A.
Grossi, F.
Levra, M. Giaj
Cavina, R.
Vigano, M.
Caligaris-Cappio, F.
Lambiase, A.
Bordignon, C.
机构：
[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[2] Univ Turin, Orbassano, Italy
[3] Ist Clin Humanitas, Rozzano, Italy
[4] Natl Inst Canc Res, Genoa, Italy
[5] Univ Turin, AUO San Luigi, Thorac Oncol Unit, Orbassano, Italy
[6] Ist Clin Humanitas, Dept Oncol, Rozzano, Italy
[7] MolMed SpA, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18043
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer (SCLC)
    Pietanza, M. C.
    Sima, C. S.
    Polley, M. R.
    Sumner, D. K.
    Travis, V.
    Heguy, A.
    Ginsberg, M. S.
    Holodny, A.
    Kris, M. G.
    Krug, L. M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S507 - S507
  • [42] FRONT-LINE CHEMOTHERAPY WITH OR WITHOUT NGR-HTNF IN NON-SMALL CELL LUNG CANCER (NSCLC)
    Gregorc, V.
    Zilembo, N.
    Grossi, F.
    De Pas, T.
    Pietrantonio, F.
    Giovannini, M.
    Rossoni, G.
    Bulotta, A.
    Lambiase, A.
    Bordignon, C.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 410 - 410
  • [43] Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
    van Laarhoven, Hanneke W. M.
    Fiedler, Walter
    Desar, Ingrid M. E.
    van Asten, Jack J. A.
    Marreaud, Sandrine
    Lacombe, Denis
    Govaerts, Anne-Sophie
    Bogaerts, Jan
    Lasch, Peter
    Timmer-Bonte, Johanna N. H.
    Lambiase, Antonio
    Bordignon, Claudio
    Punt, Cornelis J. A.
    Heerschap, Arend
    van Herpen, Carla M. L.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (04) : 1315 - 1323
  • [44] Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients
    Desar, Ingrid M. E.
    van Herpen, Carla M. L.
    van Asten, Jack J. A.
    Fiedler, Walter
    Marreaud, Sandrine
    Timmer-Bonte, Johanna N. H.
    ter Voert, Edwin G. W.
    Lambiase, Antonio
    Bordignon, Claudio
    Heerschap, Arend
    van Laarhoven, Hanneke W. M.
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2011, 80 (03) : 655 - 661
  • [45] A phase II study of combination therapy with liposomal doxorubicin and carboplatin (CBDCA) in patients (pts) with previously untreated small cell lung cancer (SCLC).
    Vorobiof, DA
    Rapoport, BL
    Slabber, CF
    Alberts, AS
    Uys, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 690S - 690S
  • [46] Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study
    Blanco, A. Calles
    Mendivil, A. F. Navarro
    de Speville, B. Doger
    Colome, E. Alvarez
    Luken, M. J. De Miguel
    Alvarez, R. M.
    Garcia, V. Moreno
    Ramon, J.
    Valles, M. Arregui
    de la Fuente, E. Corral
    Alcala, D.
    Fernandez, M.
    Morato, J. Rodriguez
    Calvo, E.
    Sanchez, R. Palmero
    Jove, M.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1060 - S1061
  • [47] A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
    Owonikoko, Taofeek Kunle
    Higgins, Kristin Ann
    Chen, Zhengjia
    Zhang, Chao
    Pillai, Rathi Narayana
    Steuer, Conor Ernst
    Saba, Nabil F.
    Pakkala, Suchita
    Shin, Dong Moon
    Zhang, Guojing
    Wang, Shuhua
    Hossain, Mohammed S.
    Beardslee, Tyler
    Engelhart, Anne
    Revenig, Janine
    Khuri, Fadlo
    Curran, Walter John, Jr.
    Lonial, Sagar
    Waller, Edmund K.
    Ramalingam, Suresh S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] A phase II trial of pazopanib in relapsed/refractory small cell lung cancer (SCLC).
    Gandhi, Leena
    Heist, Rebecca Suk
    Lucca, Joan Vern
    Temel, Jennifer S.
    Fidias, Panos
    Morse, Linda K.
    Johnson, Bruce E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Phase II study of pegylated liposomal doxorubicin: is inactive in recurrent small cell lung cancer (SCLC).
    Samantas, E
    Kalofonos, H
    Nikolaides, C
    Mylonakis, N
    Giannelou, M
    Kosmidis, P
    Linardou, H
    Skarlos, D
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 111 - 111
  • [50] NGR-hTNF plus chemotherapy as first-line therapy of non-small cell lung cancer (NSCLC).
    Gregorc, Vanesa
    Zilembo, Nicoletta
    Grossi, Francesco
    De Pas, Tommaso M.
    Rossoni, Gilda
    Pietrantonio, Filippo
    Rijavec, Erika
    Giovannini, Monica
    Citterio, Giovanni
    Lambiase, Antonio
    Bordignon, Claudio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345